MA26645A1 - Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq - Google Patents

Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq

Info

Publication number: MA26645A1
Authority: MA; Morocco
Prior art keywords: psychiotric; orphanine; neurological; receptor; compounds
Prior art date: 1998-06-12

Application number

MA25617A

Other languages

English (en)

Inventor

Geo Adam

Andrea Cesura

Francois Jenck

Sabine Kolczewski

Stephan Roever

Juergen Wichmann

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

1999-06-10

Publication date

2004-12-20

1999-06-10 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26645A1 publication Critical patent/MA26645A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Photoreceptors In Electrophotography (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA25617A 1998-06-12 1999-06-10 Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq MA26645A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98110803		1998-06-12

Publications (1)

Publication Number	Publication Date
MA26645A1 true MA26645A1 (fr)	2004-12-20

Family

ID=8232113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25617A MA26645A1 (fr)	1998-06-12	1999-06-10	Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq

Country Status (30)

Country	Link
US (1)	US6642247B2 (fr)
EP (1)	EP0963985B1 (fr)
JP (1)	JP3369123B2 (fr)
KR (1)	KR100393311B1 (fr)
CN (2)	CN1110497C (fr)
AR (1)	AR019860A1 (fr)
AT (1)	ATE234302T1 (fr)
AU (1)	AU752835B2 (fr)
BR (1)	BR9902653A (fr)
CA (1)	CA2274201C (fr)
CO (1)	CO5040061A1 (fr)
CZ (1)	CZ291323B6 (fr)
DE (1)	DE69905798T2 (fr)
DK (1)	DK0963985T3 (fr)
ES (1)	ES2194402T3 (fr)
HR (1)	HRP990187A2 (fr)
HU (1)	HUP9901910A3 (fr)
ID (1)	ID23306A (fr)
IL (1)	IL130375A0 (fr)
MA (1)	MA26645A1 (fr)
NO (1)	NO312591B1 (fr)
NZ (1)	NZ336226A (fr)
PE (1)	PE20000540A1 (fr)
PL (1)	PL333693A1 (fr)
PT (1)	PT963985E (fr)
SG (1)	SG83135A1 (fr)
TR (1)	TR199901380A2 (fr)
TW (1)	TW434241B (fr)
YU (1)	YU26799A (fr)
ZA (2)	ZA993853B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69923744T2 (de) *	1998-10-23	2006-02-23	Pfizer Inc.	1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
EP1491212B1 (fr)	2002-03-29	2012-08-08	Mitsubishi Tanabe Pharma Corporation	Remede contre les troubles du sommeil
DE102004014296A1 (de)	2004-03-22	2005-10-06	Grünenthal GmbH	Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
KR100662191B1 (ko)	2004-12-23	2006-12-27	엘지이노텍 주식회사	질화물 반도체 발광소자 및 그 제조방법
US8877779B2 (en)	2007-03-01	2014-11-04	Mitsubishi Tanabe Pharma Corporation	Benzimidazole compound and pharmaceutical use thereof
TW201016675A (en)	2008-09-16	2010-05-01	Mitsubishi Tanabe Pharma Corp	Crystalline benzoimidazole compound and salt thereof
CN109503582A (zh) *	2018-12-17	2019-03-22	上海合全药物研发有限公司	顺式螺[哌啶并-4,1＇-吡咯并[3,4-c]吡咯]-1-甲酸叔丁酯的合成方法
WO2021228123A1 (fr) *	2020-05-12	2021-11-18	北京广为医药科技有限公司	Composé permettant d'ajuster l'activité du récepteur nmda, composition pharmaceutique et utilisation associées
KR20220022988A (ko)	2020-08-20	2022-03-02	제트스타 주식회사	트랙터용 써레

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63208844A (ja) *	1987-02-26	1988-08-30	Konica Corp	有機着色物質の光褪色防止方法
US5221675A (en) *	1989-12-15	1993-06-22	Abbott Laboratories	Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) *	1990-04-10	1996-07-09	Fisher; Abraham	Spiro compounds containing five-membered rings
CA2226058C (fr) *	1997-01-30	2008-01-29	F. Hoffmann-La Roche Ag	Derives de substitution en 8 de 1,3,8-triazaspiro[4.5]decan-4-one

1999
- 1999-06-07 EP EP99110954A patent/EP0963985B1/fr not_active Expired - Lifetime
- 1999-06-07 AT AT99110954T patent/ATE234302T1/de not_active IP Right Cessation
- 1999-06-07 ES ES99110954T patent/ES2194402T3/es not_active Expired - Lifetime
- 1999-06-07 DE DE69905798T patent/DE69905798T2/de not_active Expired - Lifetime
- 1999-06-07 PT PT99110954T patent/PT963985E/pt unknown
- 1999-06-07 DK DK99110954T patent/DK0963985T3/da active
- 1999-06-08 CZ CZ19992039A patent/CZ291323B6/cs not_active IP Right Cessation
- 1999-06-08 PE PE1999000486A patent/PE20000540A1/es not_active Application Discontinuation
- 1999-06-08 ZA ZA9903853A patent/ZA993853B/xx unknown
- 1999-06-09 SG SG9902947A patent/SG83135A1/en unknown
- 1999-06-09 HU HU9901910A patent/HUP9901910A3/hu unknown
- 1999-06-09 JP JP16194399A patent/JP3369123B2/ja not_active Expired - Fee Related
- 1999-06-09 CA CA2274201A patent/CA2274201C/fr not_active Expired - Fee Related
- 1999-06-09 IL IL13037599A patent/IL130375A0/xx unknown
- 1999-06-10 ZA ZA9903901A patent/ZA993901B/xx unknown
- 1999-06-10 AR ARP990102764A patent/AR019860A1/es active IP Right Grant
- 1999-06-10 NZ NZ336226A patent/NZ336226A/xx unknown
- 1999-06-10 AU AU34986/99A patent/AU752835B2/en not_active Ceased
- 1999-06-10 MA MA25617A patent/MA26645A1/fr unknown
- 1999-06-10 CO CO99036580A patent/CO5040061A1/es unknown
- 1999-06-11 HR HR98110803.8A patent/HRP990187A2/hr not_active Application Discontinuation
- 1999-06-11 CN CN99110904A patent/CN1110497C/zh not_active Expired - Fee Related
- 1999-06-11 NO NO19992876A patent/NO312591B1/no unknown
- 1999-06-11 BR BR9902653-8A patent/BR9902653A/pt active Search and Examination
- 1999-06-11 TR TR1999/01380A patent/TR199901380A2/xx unknown
- 1999-06-11 TW TW088109813A patent/TW434241B/zh not_active IP Right Cessation
- 1999-06-11 YU YU26799A patent/YU26799A/sh unknown
- 1999-06-11 PL PL99333693A patent/PL333693A1/xx unknown
- 1999-06-11 US US09/330,724 patent/US6642247B2/en not_active Expired - Fee Related
- 1999-06-11 CN CNB991083741A patent/CN1229377C/zh not_active Expired - Fee Related
- 1999-06-12 KR KR10-1999-0021892A patent/KR100393311B1/ko not_active Expired - Fee Related
- 1999-06-14 ID IDP990575D patent/ID23306A/id unknown

Also Published As

Publication number	Publication date
HUP9901910A3 (en)	2001-11-28
AU3498699A (en)	1999-12-23
DE69905798T2 (de)	2004-02-12
CZ203999A3 (cs)	2000-03-15
ES2194402T3 (es)	2003-11-16
CZ291323B6 (cs)	2003-02-12
TR199901380A3 (tr)	2001-01-22
EP0963985B1 (fr)	2003-03-12
KR20000006135A (ko)	2000-01-25
KR100393311B1 (ko)	2003-08-02
NO992876D0 (no)	1999-06-11
TW434241B (en)	2001-05-16
SG83135A1 (en)	2001-09-18
CN1244528A (zh)	2000-02-16
EP0963985A2 (fr)	1999-12-15
CO5040061A1 (es)	2001-05-29
US20030176701A1 (en)	2003-09-18
NO312591B1 (no)	2002-06-03
JP3369123B2 (ja)	2003-01-20
CN1110497C (zh)	2003-06-04
DK0963985T3 (da)	2003-06-23
CN1242367A (zh)	2000-01-26
EP0963985A3 (fr)	2001-01-24
ATE234302T1 (de)	2003-03-15
PE20000540A1 (es)	2000-07-15
HUP9901910A2 (hu)	2000-04-28
CA2274201A1 (fr)	1999-12-12
HRP990187A2 (en)	2000-02-29
AR019860A1 (es)	2002-03-20
CA2274201C (fr)	2010-02-09
IL130375A0 (en)	2000-06-01
ZA993853B (en)	1999-12-13
HU9901910D0 (en)	1999-08-30
TR199901380A2 (xx)	2001-01-22
YU26799A (sh)	2002-03-18
BR9902653A (pt)	2000-05-02
ID23306A (id)	2000-04-05
PT963985E (pt)	2003-06-30
DE69905798D1 (de)	2003-04-17
ZA993901B (en)	1999-12-13
US6642247B2 (en)	2003-11-04
CN1229377C (zh)	2005-11-30
NO992876L (no)	1999-12-13
AU752835B2 (en)	2002-10-03
JP2000026466A (ja)	2000-01-25
NZ336226A (en)	2000-10-27
PL333693A1 (en)	1999-12-20

Publication	Publication Date	Title
EP1461323A4 (fr)	2009-11-11	Composes destines au traitement de troubles metaboliques
EP1284728A4 (fr)	2004-05-19	Medicaments destines au traitement de l'obesite
EP1399171A4 (fr)	2005-12-07	Composes d'herbes medicinales destines a la prevention et au traitement du diabete
EP0788359A4 (fr)	1998-08-19	Compositions utiles a la preparation de medicaments destines au traitement de divers troubles refractaires
EP1357908A4 (fr)	2009-07-15	Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
EP1165110A4 (fr)	2002-08-07	Antagonistes de hmg1 destines au traitement d'etats inflammatoires
EP0859637A4 (fr)	2001-11-14	Compositions destinees au traitement et au diagnostic des problemes de poids, dont l'obesite
EP1252329A4 (fr)	2004-12-22	Hypocretine et recepteurs d'hypocretine pour la regulation du sommeil et des troubles du sommeil
CH1143977H1 (fr)	2007-02-15	2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
IL116998A0 (en)	1996-09-12	Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
HK1038755A1 (zh)	2002-03-28	Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
EP1673376A4 (fr)	2010-06-23	Traitement des troubles osseux avec des modulateurs de recepteurs d'androgenes selectifs
EP1534696A4 (fr)	2010-04-07	Composes therapeutiques destines au traitement d'etats dyslipidemiques
MA26645A1 (fr)	2004-12-20	Composes destines au traitement des troubles psychiotriques, neurologiques et physiologiques lies au recepteur de l'orphanine fq
EP1539136A4 (fr)	2006-10-18	Composes selectifs des recepteurs ppar alpha destines au traitement de la dyslipidemie et d'autres troubles lipidiques
DZ3027A1 (fr)	2004-03-27	Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
HUP0201791A3 (en)	2005-02-28	The use of escitalopram for treatment of neurotic disorders
EP1060748A4 (fr)	2002-09-04	Medicaments destines aux troubles de l'epithelium corneen
FR2742052B1 (fr)	1998-04-10	Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
NO932391D0 (no)	1993-06-30	Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
EP1448193A4 (fr)	2005-11-23	Composes therapeutiques pour le traitement d'etats dyslipidemiques
GB2361872B (en)	2003-11-26	Diagnosis of medical disorders
FR2824742B1 (fr)	2003-08-29	Dispositif de reeducation des vertiges et des troubles de l'equilibre
MA26643A1 (fr)	2004-12-20	Nouveaux composes pour la preparation de medicaments pour le traitement de maladies associees au recepteur orphanine fq
GB0011430D0 (en)	2000-06-28	Acombination of therapeutic agents for treating Alzheimer's Disease